Heart failure & cardiomyopathies

The Short and Long-Term Characteristics and Outcomes of Patients with Grade 1 Myocardial Uptake on Cardiac Scintigraphy

ESC Heart FailPublished Retrospective cohort study

Main finding · SurvivalResult — go to the resultHazard ratio 0.271 95% CI 0.130–0.563

Authors' conclusion

Patients with suspected ATTR-CA and a grade 1 scintigraphy uptake demonstrate a stable clinical, laboratory, imaging, and scintigraphy phenotype along with a benign survival profile at long-term follow-up.

Study context

Population
Patients suspected for ATTR-CA (clinical and echocardiographic parameters)
Participants
132 patients
Exposure
Grade 1 vs grades 2/3 technetium pyrophosphate uptake on cardiac scintigraphy
  • Grade 1n = 89
  • Grades 2/3n = 43reference
Outcome
Final diagnosis and prognosis of patients with grade 1 uptake
Methodological detailsprospective long-term re-evaluation of grade 1 patients
  • Prospective long-term re-evaluation of grade 1 patients

Main finding

Survival · 2 [IQR 0.75, 3.25] years follow-up

Hazard ratio

0.271

95% CI 0.130–0.563

P = 0.0005

Events by group

Grade 1

7%

6 of 89

Grade 1vs Grades 2/3
HR 0.271 (95% CI 0.130–0.563); P = 0.0005

As reported in the abstract

Observational data: associations, not effects.

Further findings

Long-term re-evaluation of grade 1 patients · median 3.2 (IQR 2.2, 3.9) years

Grades 2/3 uptake at repeated scintigraphy
0/25
NYHA class, biomarker levels and echocardiography findings remained stable
  • 30 grade 1 patients re-evaluated

Baseline characteristics, grade 1 vs grades 2/3

Grade 1 younger, female predominant, lower biomarker levels and LV mass

Original publication

The Short and Long-Term Characteristics and Outcomes of Patients with Grade 1 Myocardial Uptake on Cardiac Scintigraphy. ESC Heart Fail. Published 17 February 2023. doi:10.1002/ehf2.14312

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.